Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...
On March 11, 2025, we remember the profound loss and resilience of the people of Japan following the Great East Japan ...
3don MSN
The Fukushima Daiichi nuclear power plant’s radiation levels have significantly dropped since the cataclysmic meltdown 14 ...
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
GlobalData on MSN9d
Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trialDaiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) has shown clinically meaningful 'improvement' in the ...
Interesting Engineering on MSN2d
Fukushima disaster: 14 years into Japan’s battle to remove 880 tons of nuclear debrisThe path to removing the plant’s estimated 880 tons of nuclear debris is fraught with technical and human risks ...
ECIM 2025 saw a heated discussion on whether anticoagulation in DVT should be treated like a chronic condition, as new ...
The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...
J.P. Morgan analyst Seiji Wakao maintained a Buy rating on Daiichi Sankyo Company (DSKYF – Research Report) on March 5 and set a price target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback